<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel diseases</z:e> (IBDs), particularly <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC), are associated with a variety of extra-intestinal manifestations (EIMs) </plain></SENT>
<SENT sid="1" pm="."><plain>About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract </plain></SENT>
<SENT sid="2" pm="."><plain>The EIMs associated with IBD have a negative impact on patients with UC and CD, and the resolution of most of them parallels that of the active IBD in terms of timing and required therapy; however, the clinical course of EIMs such as axial <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:hpo ids='HP_0000999'>pyoderma</z:hpo> gangrenosum, <z:hpo ids='HP_0000554'>uveitis</z:hpo>, and primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> is independent of IBD activity </plain></SENT>
<SENT sid="3" pm="."><plain>The peripheral and axial <z:hpo ids='HP_0001369'>arthritis</z:hpo> associated with IBD have traditionally been treated with simple <z:chebi fb="29" ids="35480">analgesics</z:chebi>, <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi>, steroids, <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, local steroid injections and physiotherapy, but the introduction of biological response modifiers such as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha blockers, has led to further improvements </plain></SENT>
</text></document>